这场诉讼发生在诺和诺德经历动荡的一周之后。先是该公司发布了与竞争对手礼来(LLY.US)形成鲜明对 比的惨淡的年度销售预测，随后又有消息称，Hims公司正在销售其关键新药Wegovy的廉价仿制药，这 导致诺和诺德的股价受到重创。 在周末，由于美国政府的威胁，Hims放弃了该计划。但这一决定并未阻止诺和诺德提起诉讼，该诉讼 的范围不仅限于口服药物，还包括注射剂型的司美格鲁肽的所有用途。 生产重磅GLP-1类药物的诺和诺德和礼来公司长期以来一直抱怨美国食品药品监督管理局(FDA)在阻止 廉价复合减肥药泛滥方面做得不够。几年前，由于药品供应短缺，远程医疗公司首次得以销售仿冒的减 肥药。虽然药品短缺已经结束，但这种做法仍在继续。 智通财经APP获悉，诺和诺德(NVO.US)表示将起诉Hims & Hers(HIMS.US)，指控其生产仿冒诺和诺德 减肥药。与此同时，Hims & Hers放弃了销售Wegovy减肥药仿冒版本的计划。诺和诺德公司周一声称， Hims公司侵犯了其在美国的司美格鲁肽专利，是Ozempic和Wegovy等重磅药物的活性成分。诺和诺德 还称，Hims的竞争产品可能对消费者构成潜在危险。 Hims ...

"我们很高兴找到方法，继续通过平台跨专科推出品牌治疗方案。对客户而言，平台上有更多选择是最 好的事情，"Hims首席执行官Andrew Dudum在一份声明中说。 周四，Hims&Hers Health(HIMS.US)盘前大涨近14%，报27.77美元。消息面上，据报道，该公司以每月 49美元的优惠价开始提供新推出的Wegovy药片的仿制版，较品牌药物便宜约100美元。Hims表示，该疗 法可以针对希望避免副作用或更喜欢药片而非注射选项的患者进行定制。 ...

Group 1 - The CEO of GPCR, Raymond Stevens, expressed concerns about the influx of generic versions of their experimental weight loss drug, which has not yet been approved [1] - Following the launch of weight loss injections by Eli Lilly and Novo Nordisk, patients turned to generics due to supply shortages, although these shortages have since ended [1] - The CEO of Novo Nordisk indicated that up to 1.5 million patients in the U.S. are using compounded weight loss drugs, highlighting the ongoing issue of generics in the market [1] Group 2 - Pharmaceutical companies claim that the FDA has not done enough to prevent the spread of generics, with a recent statement indicating plans to publish a list of overseas suppliers that meet FDA standards [2] - Compounding pharmacies utilize these raw materials to produce their own branded generic versions of drugs like Wegovy and Zepbound [2] Group 3 - Stevens noted that GPCR's aleniglipron is a small molecule drug with a more complex manufacturing process, making it harder to replicate compared to peptide drugs like Zepbound and Wegovy from Eli Lilly and Novo Nordisk [1]